Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content
Tables

Table B2. Government Performance and Results Act (GPRA) Sexually Transmitted Diseases Goals, Measures, and Target

GPRA Goals Actual Target
2014 2015 2016 2017
Goal 1: Reduction in PID (as measured by initial visits to physicians in women 15–44 years of age) 98,800 68,000 N/A 86,423
a. Proportion of high-risk women aged 16-20 infected with chlamydia* 13.9% 13.4% 12.3% 11.7%
b. Proportion of high-risk women aged 21-24 infected with chlamydia*† 7.3% 8.5% 7.4% 8.3%
c. Rate of gonorrhea/100,000 population  in women aged 16-20 523.9 537.0 586.0 523.9
d. Rate of gonorrhea/100,000 population in women aged 21-24 508.1 523.9 573.0 511.8
e. Black: white ratio of gonorrhea in women aged 16-24  10.3 9.5 8.4 10.1
f. Proportion of sexually active females aged 16-20 years enrolled in Medicaid who are screened for chlamydia infections 52.3% 51.2% N/A 62.5%
g. Proportion of sexually active females aged 21-24 years enrolled in Medicaid who are screened for chlamydia infections 62.0% 60.1% N/A 66.0%
h. Proportion of sexually active females aged 16-20 years enrolled in commercial health insurance plans who are screened for chlamydia infections 42.7% 42.4% N/A 43.5%
i. Proportion of sexually active females aged 21-24 years enrolled in commercial health insurance plans who are screened for chlamydia infections 52.1% 52.4% N/A 52.7%
Goal 2: Elimination of Congenital Syphilis a. Incidence of P&S syphilis/100,000 population in women aged 15-44 2.6 3.2 4.2 0.8
b. Incidence of congenital syphilis/100,000 live births 11.5 12.4 15.7 6.2
c. Proportion of pregnant women that are screened for syphilis at least one month before delivery 85.9% 84.0% N/A 84.0%
 
GPRA Goals Data Source
1 National Disease and Therapeutic Index (IMS Health)
1a, 1b National Job Training Program (NJTP)
1c, 1d, 1e National Notifiable Disease Surveillance System (NNDSS), CDC
1f, 1g, 1h, 1i Healthcare Effectiveness Data and Information Set (HEDIS), National Committee for Quality Assurance (NCQA)
2a, 2b National Notifiable Disease Surveillance System (NNDSS), CDC
2c MarketScan Commercial Claims and Encounters Database, Truven Health Analytics

NOTE: Data presented in this table reflect data reported to GPRA in current and prior years. Data for years prior to 2016 may not match estimates presented in other sections of this report.
* Median state-specific chlamydia prevalence/positivity among states with >100 females in this age group entering the National Job Training Program.
† In FY 2013 CDC improved the calculation of these data to increase the stability of estimate over time. Data for 2010 and later years reflect this improved calculation method.
GPRA = Government Performance and Results Act; PID = pelvic inflammatory disease; P&S = primary and secondary.

TOP